Connect with us
Prague Gaming & TECH Summit 2025 (25-26 March)

Fintech PR

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

Published

on

domain-therapeutics-and-chime-biologics-announce-manufacturing-agreement-to-advance-novel-anti-ccr8-antibody-for-cancer-immunotherapy
  • The agreement combines Domain Therapeutics’ candidate DT-7012 with Chime Biologics’ internationally-recognized manufacturing expertise 
  • In June 2023, Domain nominated DT-7012, a Treg depleting anti-CCR8 monoclonal antibody (mAb) with best-in-class potential, which enters Phase I studies in 2025
  • The CCR8 GPCR target is a highly strategic approach in immuno-oncology to increase clinical success rates in non-responding patients

STRASBOURG, France, BOSTON and SHANGHAI, March 12, 2024 /PRNewswire/ — Domain Therapeutics (“Domain”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), and Chime Biologics, a leading Contract Development and Manufacturing Organization (CDMO) that enables its partners’ success in biologics, today announce the signing of a manufacturing service agreement for the production of Domain’s best-in-class Treg depleting anti-CCR8 antibody candidate, DT-7012. This phase of manufacturing aims to deliver an effective therapeutic for cancer patients worldwide.

Under the terms of the agreement, Chime Biologics will ensure stable cell line development (CLD) and DT-7012 candidate manufacturing to support clinical trials in strategic countries. Chime Biologics’ first global modular facility with single-use bioprocessing technology meets international cGMP standards with proven audit track records.

DT-7012 is a novel anti-CCR8 mAb depleting tumor-infiltrating Tregs, major immunosuppressive cells. Treg depletion with anti-CCR8 mAb has demonstrated a unique anti-tumor potency as a monotherapy. DT-7012 has a proven best-in-class potential compared to other clinical-stage CCR8 antibodies, paving the way for effective GPCR-targeting immunotherapies, aiming to activate anti-tumor immunity for cancer patients unresponsive to other treatments. Phase I clinical studies of DT-7012 are expected to start in early 2025 for solid tumors and mid-2025 for cutaneous T-cell lymphoma (CTCL).

Dr. Jimmy Wei, President of Chime Biologics, commented: “We look forward to progressing this strategic partnership, which combines Domain’s leading anti-CCR8 antibody candidate with Chime Biologics’ CLD to commercial manufacturing expertise, contributing to the development of DT-7012 for various cancers”.

Stephan Schann, Chief Scientific Officer of Domain Therapeutics, said: “We’re thrilled to collaborate with Chime Biologics, a great scientific and manufacturing expert, to advance DT-7012, our leading anti-CCR8 candidate, to the next development stage. This new GPCR-targeting immunotherapy has immense potential to unlock the immune system’s cancer fighting abilities and help patients globally. At Domain, we prioritize precision research and innovation and embrace new partnerships with organizations that share our vision and passion to advance immuno-oncology”.

View original content:https://www.prnewswire.co.uk/news-releases/domain-therapeutics-and-chime-biologics-announce-manufacturing-agreement-to-advance-novel-anti-ccr8-antibody-for-cancer-immunotherapy-302085515.html

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Verlingue consolidates its position in Europe with the acquisition of ProConseils Solutions

Published

on

verlingue-consolidates-its-position-in-europe-with-the-acquisition-of-proconseils-solutions

QUIMPER, France, Nov. 27, 2024 /PRNewswire/ — The insurance broker Verlingue, a subsidiary of the Adelaïde Group, announces its acquisition of ProConseils Solutions, a major player in the insurance brokerage market in French-speaking Switzerland. This strategic operation will enable Verlingue to strengthen its position in the Swiss market by broadening its range of services and expertise in the field of insurance coverage for businesses, local authorities and medico-social establishments.

ProConseils Solutions was founded in 2003 and is known for its personalised client approach and commitment to quality. With a staff of almost 25 employees based in three offices in the Canton of Vaud, ProConseils Solutions works with more than 1,500 companies, nearly 150 local authorities and 30 medico-social establishments, providing them with optimised solutions for managing their insurance coverage.

This acquisition is fully aligned with Verlingue’s Better Future 28 strategic plan, which aims to reinforce the company’s presence in Europe and expand the territorial coverage of its business, based on an ambitious project bringing together local businesses with a shared vision.

Benjamin Verlingue, Chairman and CEO of the Adelaïde Group, explains that:

“The acquisition of ProConseils Solutions marks an important step in our growth strategy in Switzerland and Europe.  We share strong values with ProConseils Solutions, notably close relations with our customers and service excellence. Joining forces will enable us to provide all our customers – whether in Switzerland or in the other countries in which we operate – an even broader range of expertise and solutions that are increasingly tailored to their needs.”

Alain Bornand and Joseph Gelsomino, co-Founders of ProConseils Solutions, add:

“Becoming part of Verlingue and the Adelaïde Group, is a real opportunity for our customers and our staff. We will be able to provide even better services and draw on the Group’s technical expertise and international dimension. It will also enable us to continue to develop ProConseils Solutions in French-speaking Switzerland, both through our existing teams and through possible acquisitions. ProConseils Solutions is entering a new phase in its evolution and we are looking forward to sharing this with our customers, partners and staff.”

With this acquisition, Verlingue will help the Adelaïde Group achieve its objective of becoming the leading family-owned insurance broker in Europe by 2028.

About Verlingue

Verlingue is an insurance broker specialising in business protection, and a subsidiary of the Adelaïde Group. Working alongside entrepreneurs, Verlingue’s goal is to harness corporate risk management and employee protection to drive its customers’ value creation and performance.  With offices in France, Portugal, Switzerland, the United Kingdom and Italy, and through partners in over 100 countries, Verlingue works with its customers over the long term and at every instant to better understand and plan ahead for new risks and develop simple yet effective solutions to protect their business (corporate risk) and staff (supplementary social protection schemes and pensions).

Advertisement

1,500 employees, 550 of whom are based outside France

Operating out of 5 countries in Europe

LinkedIn / www.verlingue.fr

Media Contact: 
Agence Epoka – Lucie Fortin[email protected] – +33 (0)6 19 68 70 18

About ProConseils Solutions

ProConseils Solutions is an insurance broker that specialises in providing insurance advice and coverage to local authorities, socio-medical establishments and SMEs. Our team has extensive expertise, based on nationally-recognised higher occupational training, supported by many years’ experience in the field. With local offices in Morges, Yverdon-les-Bains and Payerne, we are close to our customers. Respect, competency, high standards and team spirit are the values that underpin our corporate charter.

Media contact for ProConseils Solutions and Verlingue Switzerland:
Verlingue SA – Nicole Maissen – Marketing & Communications Manager – [email protected] – Telephone +41 58 414 45 20

Logo – https://mma.prnewswire.com/media/2568709/Verlingue_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/verlingue-consolidates-its-position-in-europe-with-the-acquisition-of-proconseils-solutions-302317560.html

Continue Reading

Fintech

Former MD of SUI Foundation, Greg Siourounis, Joins xMoney Global as Co-Founder and CEO to build MiCA-Regulated Stablecoin Platform

Published

on

former-md-of-sui-foundation,-greg-siourounis,-joins-xmoney-global-as-co-founder-and-ceo-to-build-mica-regulated-stablecoin-platform

xMoney Global, the global, inter-bank and cross crypto/fiat integrated payments platform has appointed award-winning economist Dr. Greg Siourounis as Co-Founder and CEO. The company is a Mastercard principal member, with strategic European licenses, such as e-Money and VASP.

As the digital landscape continues to evolve with the coming MiCA regulation, xMoney Global intends to lead Europe into this new transformative EU regulated stablecoin era. Greg Siourounis will lead the integration of xMoney’s advanced blockchain-enabled payments infrastructure with its upcoming stablecoin program. Stablecoins are a key driver of blockchain adoption in today’s market, now surpassing Bitcoin, remittances, and PayPal in annual transaction volume. As such, xMoney’s Global reputation positions it to bridge Web3 innovation with traditional finance, leading Europe into a new transformative EU regulated stablecoin era.

Dr. Greg, who has played a pioneering role in the growth of Sui Foundation as its former Managing Director and who previously founded Everypay, will drive xMoney Global’s next wave of growth. Beyond the standard reference of his academic work in 2024’s Nobel Prize in Economics, Dr. Greg’s career is also decorated with awards such as the 2005 Young Economist Award from The European Economic Association and the 2008 Austin Robinson Prize from The Royal Economic Society. His immediate target will be to focus on partnerships, regulatory alignment and market expansion, as xMoney Global looks to build a comprehensive payments platform that bridges legacy financial systems with the potential of decentralized finance.

Commenting on his appointment, Dr. Greg Siourounis, CEO of xMoney Global, said, “As Europe prepares to embrace MiCA regulation, xMoney Global is positioned to redefine what compliant, secure, and seamless digital payments can be. Our goal is to deliver a solid and trusted ecosystem that combines the strengths of traditional finance with the flexibility of blockchain technology to create a future-ready payment experience.”

Beniamin Mincu, Co-founder of MultiversX, said, “xMoney Global’s mission aligns perfectly with the vision of MultiversX to bring scalable and secure blockchain solutions to mainstream finance. This appointment marks a significant step toward building a more inclusive and resilient financial system.”

The launch of xMoney Global aims to offer a next-gen blockchain-as-a-service module backed by its native stablecoin, with key white-labeled services including acquiring, issuing, onramps/offramps and a sticky loyalty program, all backed by MultiversX’s state-of-the-art sharding technology. Following the surge in crypto markets after Trump’s pro-crypto Presidential win, xMoney will be ideally placed to accelerate real-world adoption as the easiest way for everyone (consumers, retail and e-commerce) to seamlessly access fiat and crypto currencies in an app, card or payment gateway.

The post Former MD of SUI Foundation, Greg Siourounis, Joins xMoney Global as Co-Founder and CEO to build MiCA-Regulated Stablecoin Platform appeared first on News, Events, Advertising Options.

Continue Reading

Fintech PR

Slice Mobile launches special Black Friday offers

Published

on

slice-mobile-launches-special-black-friday-offers

Double Data Deal for Life

LONDON, Nov. 27, 2024 /PRNewswire/ — In anticipation of Black Friday, Slice Mobile is enhancing its popular plans—Mini, Middy, and Biggie—by offering double the data. Both new and existing customers can benefit from this upgrade for life, as long as they remain on the same plan.

Available Deals:

  • Mini Plan: Now 20GB for £10
  • Middy Plan: Now 60GB for £15
  • Biggie Plan: Now 200GB for £20
  • Bigger Biggie Plan: Already unlimited at £30

Unlimited Plan for £5 for 3 Months

For a limited time, Slice Mobile is offering the Bigger Biggie unlimited plan for just £5 per month for the first three months. Normally priced at £30, customers can access this discount by applying the promo code FIVER at checkout. With eSIM technology, users can connect within minutes without waiting for a physical SIM card.

Key Benefits of the Offer:

  • Unlimited data, texts, and calls, eliminating mid-month worries.
  • Instant eSIM setup through the app, bypassing delivery delays.
  • EU roaming up to 30GB included.
  • Flexible, rolling monthly plan.
  • A 7-day free trial to experience the service risk-free.
  • An impressive 83% discount on the first three months, saving £75 in total.
  • Simple sign-up: apply promo code FIVER at checkout.

This limited-time offer is available until 11th December 2024, making it the perfect opportunity for those seeking a flexible and affordable mobile plan.

How to Get Started

New users can join Slice Mobile, or current users can switch their free trial to a paid plan via the Slice app during the promotional period.

View original content:https://www.prnewswire.co.uk/news-releases/slice-mobile-launches-special-black-friday-offers-302317430.html

Continue Reading

Trending